Cardiology News

RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories today announced launch of Sugammadex Injection of Single-Dose Vials, a generic equivalent of Bridion®, in the United States....

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has completed the previously disclosed divestiture of its OEM business to Montagu and Kohlberg, for $1.5 billion in cash. The close of the OEM transaction marks a pivotal milestone in Teleflex's transformation strategy, sharpening the Company's focus on the commercial excellence of its continuing businesses. The divestiture strengthens Teleflex's financial flexibi...

MINNEAPOLIS--(BUSINESS WIRE)--Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce the launch of Imricor Cardiovascular, a new vertical that expands the interventional MR (iMR) market for Imricor alongside its electrophysiology and ablation business. Following recent FDA clearances for NorthStar® and the Vision-MR® Diagnostic Catheter, Imricor Cardiovascular gives U.S. hospitals an opportunity to establish early leadership in radiation-free cardiac catheterizatio...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (“ULTA”) system under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”).The patient, who presented with non-ischemic cardiomyopath...

FERNANDINA BEACH, Fla.--(BUSINESS WIRE)--The Family Heart Foundation, a leading research, education and advocacy organization, today announced that Founder and Chief Executive Officer Katherine Wilemon has been named the 2026 Honorary Fellow Awardee by the American Society for Preventive Cardiology (ASPC), one of the nation's leading professional societies dedicated to advancing cardiovascular disease prevention. The award was presented during the ASPC 2026 Congress on Cardiovascular Disease Pre...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global, pivotal Phase 2 trial of RP-A501 in Danon disease. Early safety has been promising with t...

PROVIDENCE, R.I.--(BUSINESS WIRE)--Cardiovascular Institute of New England (“CINE”) is issuing this notice about a data security incident that may have resulted in unauthorized access to certain personal and protected health information of its employees and patients. Please know that CINE moved swiftly to investigate and remediate the incident. Information about the incident, CINE’s response, and the steps consumers may take to help protect their information are detailed below. Importantly, CIN...

SAN FRANCISCO--(BUSINESS WIRE)--Cleerly, a leader in advanced cardiac imaging analysis, and Allelica, a precision medicine company specializing in multi-ancestry polygenic risk scores (PRS), today announced a partnership to launch the Cleerly Polygenic Cardiovascular Risk Score Test, powered by Allelica. The test gives physicians a new option to identify and evaluate individuals with an inherited predisposition to coronary plaque. The Cleerly Polygenic Cardiovascular Risk Score Test can be used...

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva Bio” or the “Company”), a clinical-stage biotechnology company advancing the development of a portfolio of once-weekly oral candidates for obesity and obesity-related disorders, today announces that the first patient has been dosed in a Phase 1 SAD study evaluating VRB-103, a once-weekly selective oral amylin analog, as a treatment for overweight and obesity. The Phase 1 randomized, double-blind, placebo-controlled study wil...